Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea

Munjae Lee, Mankyu Choi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value. Methods: The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis. Results: In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's q was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (t-2 and t-5, respectively) were statistically significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (t-1, t-3, and t-4, respectively) were not statistically significant. Conclusion: R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.

Original languageEnglish
Article number276
Pages (from-to)241-248
Number of pages8
JournalOsong Public Health and Research Perspectives
Volume6
Issue number4
DOIs
Publication statusPublished - 2015 Aug 1

Fingerprint

Drug Industry
Korea
Biosimilar Pharmaceuticals
Research
Pharmaceutical Preparations
Information Services
Health Expenditures
Demography

Keywords

  • Enterprise value
  • Pharmaceutical industry
  • Research and development investment
  • Time-lag effect

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea. / Lee, Munjae; Choi, Mankyu.

In: Osong Public Health and Research Perspectives, Vol. 6, No. 4, 276, 01.08.2015, p. 241-248.

Research output: Contribution to journalArticle

@article{c123ce2e29804b77a4db279c52d254d3,
title = "Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea",
abstract = "Objectives: The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value. Methods: The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis. Results: In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's q was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (t-2 and t-5, respectively) were statistically significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (t-1, t-3, and t-4, respectively) were not statistically significant. Conclusion: R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.",
keywords = "Enterprise value, Pharmaceutical industry, Research and development investment, Time-lag effect",
author = "Munjae Lee and Mankyu Choi",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.phrp.2015.07.001",
language = "English",
volume = "6",
pages = "241--248",
journal = "Osong Public Health and Research Perspectives",
issn = "2210-9099",
publisher = "Elsevier Korea",
number = "4",

}

TY - JOUR

T1 - Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea

AU - Lee, Munjae

AU - Choi, Mankyu

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objectives: The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value. Methods: The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis. Results: In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's q was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (t-2 and t-5, respectively) were statistically significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (t-1, t-3, and t-4, respectively) were not statistically significant. Conclusion: R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.

AB - Objectives: The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value. Methods: The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis. Results: In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's q was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (t-2 and t-5, respectively) were statistically significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (t-1, t-3, and t-4, respectively) were not statistically significant. Conclusion: R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.

KW - Enterprise value

KW - Pharmaceutical industry

KW - Research and development investment

KW - Time-lag effect

UR - http://www.scopus.com/inward/record.url?scp=84942194964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942194964&partnerID=8YFLogxK

U2 - 10.1016/j.phrp.2015.07.001

DO - 10.1016/j.phrp.2015.07.001

M3 - Article

AN - SCOPUS:84942194964

VL - 6

SP - 241

EP - 248

JO - Osong Public Health and Research Perspectives

JF - Osong Public Health and Research Perspectives

SN - 2210-9099

IS - 4

M1 - 276

ER -